# Plain Language Summary: Pharmaceutical Supply Chain Security Act

This bill is designed to make sure that the medicines and drugs you buy are safe and haven't been tampered with or counterfeited. Right now, pharmaceuticals move through a complex network of manufacturers, wholesalers, and pharmacies before reaching patients, and there are gaps in tracking where drugs come from and who handles them. This bill creates stronger requirements for companies involved in selling and distributing medications to keep detailed records and verify that the drugs they're handling are legitimate.

The main impact is that pharmaceutical companies, wholesalers, and pharmacies will need to implement new tracking systems and documentation procedures. They'll have to maintain records about where medications come from and where they go, similar to how food companies track products through the supply chain. If a counterfeit or contaminated drug is discovered, these records will help authorities quickly identify where it entered the system and pull it from shelves. Companies that don't comply with these requirements could face penalties.

For patients and consumers, this means better protection against fake medications and contaminated drugs reaching the market. If you take prescription medications, this bill makes it less likely you'll accidentally receive a counterfeit version that could be ineffective or even dangerous. The downside is that these new tracking requirements could potentially increase costs for pharmaceutical companies, which might eventually be passed along to consumers through higher drug prices, though the bill aims to balance safety with affordability. Overall, the bill prioritizes making sure the medications in your medicine cabinet are genuine and safe.

Pharmaceutical Supply Chain Security Act

Lankford, James

Pharmaceutical Supply Chain Security ActThis bill directs certain agencies to report on and reduce the role of China in pharmaceutical supply chains.Specifically, the Food and Drug Administration must report on pharmaceutical products and ingredients for which China supplies more than 20% of the quantities available in the United States. In addition, the President must develop a strategy to address the role of China in the global pharmaceutical supply chain and related threats to national security. The United States International Development Finance Corporation must also support manufacturing projects that promote the security of pharmaceutical supply chains, reduce reliance on China, and foster cooperation with other countries.